TY - JOUR

T1 - Biomarker counseling, disclosure of diagnosis and follow-up in patients with mild cognitive impairment

T2 - A European Alzheimer's disease consortium survey

AU - Frederiksen, Kristian S.

AU - Nielsen, Thomas R.

AU - Appollonio, Ildebrando

AU - Andersen, Birgitte Bo

AU - Riverol, Mario

AU - Boada, Mercè

AU - Ceccaldi, Mathieu

AU - Dubois, Bruno

AU - Engelborghs, Sebastiaan

AU - Frölich, Lutz

AU - Hausner, Lucrezia

AU - Gabelle, Audrey

AU - Gabryelewicz, Tomasz

AU - Grimmer, Timo

AU - Hanseeuw, Bernard

AU - Hort, Jakub

AU - Hugon, Jacques

AU - Jelic, Vesna

AU - Koivisto, Anne

AU - Kramberger, Milica G.

AU - Lebouvier, Thibaud

AU - Lleó, Alberto

AU - de Mendonça, Alexandre

AU - Nobili, Flavio

AU - Ousset, Pierre Jean

AU - Perneczky, Robert

AU - Olde Rikkert, Marcel

AU - Robinson, David

AU - Rouaud, Olivier

AU - Sánchez, Elisabet

AU - Santana, Isabel

AU - Scarmeas, Nikolaos

AU - Sheardova, Katerina

AU - Sloan, Stephanie

AU - Spiru, Luiza

AU - Stefanova, Elka

AU - Traykov, Latchezar

AU - Yener, Görsev

AU - Waldemar, Gunhild

N1 - Funding Information: Kristian S. Frederiksen, T Rune Nielsen, Ildebrando Appollonio, Birgitte Bo Andersen, Mario Riverol, Mercè Boada, Mathieu Ceccaldi, Bruno Dubois, Sebastiaan Engelborghs, Lutz Frölich, Lucrezia Hausner, Audrey Gabelle, Tomasz Gabryelewicz, Bernard Hanseeuw, Jakub Hort, Jacques Hugon, Vesna Jelic Anne Koivisto, Milica G. Kramberger, Thibaud Lebouvier, Alberto Lleó, Alexandre de Mendonça, Flavio Nobili, Pierre‐Jean Ousset, Robert Perneczky, Marcel Olde Rikkert, David Robinson, Olivier Rouaud, Elisabet Sánchez, Isabel Santana, Katerina Sheardova, Stephanie Sloan, Luiza Spiru, Elka Stefanova, Latchezar Traykov, Görsev Yener, Gunhild Waldemar have no conflicts of interest regarding this manuscript. Outside the submitted work Dr. Grimmer reported having received consulting fees from Actelion, Biogen, Eli Lilly, Iqvia/Quintiles; MSD; Novartis, Quintiles, Roche Pharma, lecture fees from Biogen, Lilly, Parexel, Roche Pharma, and grants to his institution from Actelion and PreDemTech. Outside the submitted work Dr. Scarmeas reports grants from Alzheimer's Association, grants from European Social Fund, grants from Ministry for Health Greece, during the conduct of the study; personal fees from Merck Consumer Health, personal fees from NIH, grants from EISAI, personal fees from EISAI Korea, grants from EPAD. Publisher Copyright: © 2020 John Wiley & Sons Ltd.

PY - 2021

Y1 - 2021

N2 - Objectives: Mild cognitive impairment (MCI) is associated with an increased risk of further cognitive decline, partly depending on demographics and biomarker status. The aim of the present study was to survey the clinical practices of physicians in terms of biomarker counseling, management, and follow-up in European expert centers diagnosing patients with MCI. Methods: An online email survey was distributed to physicians affiliated with European Alzheimer's disease Consortium centers (Northern Europe: 10 centers; Eastern and Central Europe: 9 centers; and Southern Europe: 15 centers) with questions on attitudes toward biomarkers and biomarker counseling in MCI and dementia. This included postbiomarker counseling and the process of diagnostic disclosure of MCI, as well as treatment and follow-up in MCI. Results: The response rate for the survey was 80.9% (34 of 42 centers) across 20 countries. A large majority of physicians had access to biomarkers and found them useful. Pre- and postbiomarker counseling varied across centers, as did practices for referral to support groups and advice on preventive strategies. Less than half reported discussing driving and advance care planning with patients with MCI. Conclusions: The variability in clinical practices across centers calls for better biomarker counseling and better training to improve communication skills. Future initiatives should address the importance of communicating preventive strategies and advance planning.

AB - Objectives: Mild cognitive impairment (MCI) is associated with an increased risk of further cognitive decline, partly depending on demographics and biomarker status. The aim of the present study was to survey the clinical practices of physicians in terms of biomarker counseling, management, and follow-up in European expert centers diagnosing patients with MCI. Methods: An online email survey was distributed to physicians affiliated with European Alzheimer's disease Consortium centers (Northern Europe: 10 centers; Eastern and Central Europe: 9 centers; and Southern Europe: 15 centers) with questions on attitudes toward biomarkers and biomarker counseling in MCI and dementia. This included postbiomarker counseling and the process of diagnostic disclosure of MCI, as well as treatment and follow-up in MCI. Results: The response rate for the survey was 80.9% (34 of 42 centers) across 20 countries. A large majority of physicians had access to biomarkers and found them useful. Pre- and postbiomarker counseling varied across centers, as did practices for referral to support groups and advice on preventive strategies. Less than half reported discussing driving and advance care planning with patients with MCI. Conclusions: The variability in clinical practices across centers calls for better biomarker counseling and better training to improve communication skills. Future initiatives should address the importance of communicating preventive strategies and advance planning.

KW - Alzheimer's disease

KW - biomarker counseling

KW - biomarkers

KW - dementia

KW - diagnosis

KW - diagnostic disclosure

KW - mild cognitive impairment

KW - survey

U2 - 10.1002/gps.5427

DO - 10.1002/gps.5427

M3 - Journal article

C2 - 32896040

AN - SCOPUS:85090978657

VL - 36

SP - 324

EP - 333

JO - International Journal of Geriatric Psychiatry

JF - International Journal of Geriatric Psychiatry

SN - 0885-6230

IS - 2

ER -